Unknown

Dataset Information

0

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.


ABSTRACT: We assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n?=?142) were randomized 2?:?1 into two different treatment groups as follows: 99 received teneligliptin (20?mg) and 43 received placebo. The primary endpoint was change in glycated haemoglobin (HbA1c) level from baseline to week 24. Teneligliptin significantly reduced the HbA1c level from baseline compared with placebo after 24?weeks. At week 24, the differences between changes in HbA1c and fasting plasma glucose (FBG) in the teneligliptin and placebo groups were -0.94% [least-squares (LS) mean -1.22, -0.65] and -1.21?mmol/l (-1.72, -0.70), respectively (all p?

SUBMITTER: Hong S 

PROVIDER: S-EPMC5069603 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.

Hong S S   Park C-Y CY   Han K A KA   Chung C H CH   Ku B J BJ   Jang H C HC   Ahn C W CW   Lee M-K MK   Moon M K MK   Son H S HS   Lee C B CB   Cho Y-W YW   Park S-W SW  

Diabetes, obesity & metabolism 20160318 5


We assessed the 24-week efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus (T2DM) that was inadequately controlled with diet and exercise. The present study was designed as a multicentre, randomized, double-blind, placebo-controlled, parallel-group, phase III study. Patients (n = 142) were randomized 2 : 1 into two different treatment groups as follows: 99 received teneligliptin (20 mg) and 43 received placebo. The pri  ...[more]

Similar Datasets

| S-EPMC6680285 | biostudies-literature
| S-EPMC5484989 | biostudies-literature
| S-EPMC9442496 | biostudies-literature
| S-EPMC6612358 | biostudies-literature
| S-EPMC5846888 | biostudies-literature
| S-EPMC6162004 | biostudies-literature
| S-EPMC8519978 | biostudies-literature
| S-EPMC4576018 | biostudies-literature
2011-12-31 | E-MTAB-583 | biostudies-arrayexpress
| S-EPMC10712048 | biostudies-literature